DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 022081/S-022 SUPPLEMENT APPROVAL

Gilead Sciences, Inc.
Attention: Ellen L. Shen, Ph.D.
Associate Manager, Regulatory Affairs
333 Lakeside Dr.
Foster City, CA 94404

Dear Dr. Shen:

Please refer to your supplemental New Drug Application (sNDA) dated March 14, 2012, received March 15, 2012, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Letairis (ambrisentan) 5 and 10 mg Tablets.

We also acknowledge receipt of your amendments dated August 24 and September 13, 2012, and your risk evaluation and mitigation strategy (REMS) assessment dated August 9, 2012.

This Prior Approval sNDA provides for revisions to the labeling and related proposed modifications to the approved REMS for Letairis (ambrisentan).

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

LABELING CHANGES

In the HIGHLIGHTS section of the package insert:

- Added text in CONTRAINDICATIONS
- Idiopathic Pulmonary Fibrosis (4.2)
- Revised text under RECENT MAJOR CHANGES
- Revised the Table of Contents to reflect updated labeling text.

In the FULL PRESCRIBING INFORMATION section of the package insert:
Added text in CONTRAINDICATIONS

4.2 Idiopathic Pulmonary Fibrosis
LETAIRIS is contraindicated in patients with Idiopathic Pulmonary Fibrosis (IPF) including IPF patients with pulmonary hypertension (WHO Group 3) [see Clinical Studies (14.3)].

Added three adverse events in ADVERSE REACTIONS/Postmarketing Experience
asthenia, dizziness, and fatigue

Added text in CLINICAL STUDIES

14.3 Adverse Effects in Idiopathic Pulmonary Fibrosis (IPF)
A randomized controlled study in patients with IPF, with or without pulmonary hypertension (WHO Group 3), compared LETAIRIS (n=329) to placebo (n=163). The study was terminated after 34 weeks for lack of efficacy, and was found to demonstrate a greater risk of disease progression or death on LETAIRIS. More patients taking LETAIRIS died (8% vs. 4%), had a respiratory hospitalization (13% vs. 6%), and had a decrease in FVC/DLCO (17% vs. 12%) [see Contraindications (4.2)].

In the MEDICATION GUIDE:
Under Who should not take LETAIRIS?
Added you have a condition called Idiopathic Pulmonary Fibrosis (IPF).

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, using the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format, as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm, that is identical to the enclosed labeling (text for the package insert, Medication Guide) and include the labeling changes proposed in any pending “Changes Being Effected” (CBE) supplements and any annual reportable changes not included in the enclosed labeling. Information on submitting SPL files using eLIST may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.
The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

We request that the labeling approved today be available on your website within 10 days of receipt of this letter.

RISK EVALUATION AND MITIGATION STRATEGY REQUIREMENTS

The REMS for Letairis (ambrisentan) was originally approved on May 29, 2009, and REMS modifications were approved on July 1 and August 5, 2009, August 24 and October 13, 2010, March 3, 2011, and February 15, 2012. The REMS consists of a Medication Guide, elements to assure safe use, an implementation system, and a timetable for submission of assessments of the REMS. Your proposed modification to the REMS consists of the above revisions to the Medication Guide and revisions to relevant sections of the appended REMS materials, specifically, the REMS website, to align the content with the above referenced labeling changes.

Your proposed modified REMS, submitted on September 13, 2012, and appended to this letter, is approved.

The timetable for submission of assessments of the REMS will remain the same as that approved on August 24, 2010.

There are no changes to the REMS assessment plan described in our March 3, 2011 letter.

In addition to the assessments submitted according to the timetable included in the approved REMS, you must submit a REMS assessment and may propose a modification to the approved REMS when you submit a supplemental application for a new indication for use as described in section 505-1(g)(2)(A) of FDCA.

If the assessment instruments and methodology for your REMS assessments are not included in the REMS supporting document, or if you propose changes to the submitted assessment instruments or methodology, you should update the REMS supporting document to include specific assessment instrument and methodology information at least 90 days before the assessments will be conducted. Updates to the REMS supporting document may be included in a new document that references previous REMS supporting document submission(s) for unchanged portions. Alternatively, updates may be made by modifying the complete previous REMS supporting document, with all changes marked and highlighted. Prominently identify the submission containing the assessment instruments and methodology with the following wording in bold capital letters at the top of the first page of the submission:
NDA 22081 REMS CORRESPONDENCE
(insert concise description of content in bold capital letters, e.g.,
UPDATE TO REMS SUPPORTING DOCUMENT - ASSESSMENT
METHODOLOGY)

An authorized generic drug under this NDA must have an approved REMS prior to marketing. Should you decide to market, sell, or distribute an authorized generic drug under this NDA, contact us to discuss what will be required in the authorized generic drug REMS submission.

Prominently identify submissions containing the REMS assessments or proposed modifications of the REMS with the following wording in bold capital letters at the top of the first page of the submission as appropriate:

NDA 022081
REMS ASSESSMENT

NEW SUPPLEMENT FOR NDA 022081 - PRIOR APPROVAL SUPPLEMENT
PROPOSED REMS MODIFICATION
REMS ASSESSMENT

NEW SUPPLEMENT (NEW INDICATION FOR USE)
FOR NDA 022081
REMS ASSESSMENT
PROPOSED REMS MODIFICATION (if included)

If you do not submit electronically, please send 5 copies of REMS-related submissions.

LETTERS TO HEALTH CARE PROFESSIONALS

If you decide to issue a letter communicating important safety-related information about this drug product (i.e., a “Dear Health Care Professional” letter), we request that you submit, at least 24 hours prior to issuing the letter, an electronic copy of the letter to this NDA to the following address:

MedWatch Program
Office of Special Health Issues
Food and Drug Administration
10903 New Hampshire Ave
Building 32, Mail Stop 5353
Silver Spring, MD 20993

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, please call Dan Brum, Pharm.D., RAC, Regulatory Project Manager, at (301)796-0578.

Sincerely,

{See appended electronic signature page}

Mary Ross Southworth, Pharm.D.
Deputy Director of Safety
Division of Cardiovascular and Renal Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

Enclosures:
  Package Insert
  Medication Guide
  Modified REMS
  REMS Materials
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MARY R SOUTHWORTH
10/19/2012